Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 5Neoplasms 3Lymphoma 3Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Esophageal Neoplasms 2Bone Marrow Diseases 2Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1

Interventions

Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Registries 1Patient Reported Outcome Measures 1Nicotine Chewing Gum 1Interviews as Topic 1Cisplatin 1Bupropion 1Bleomycin 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Second Primary × Patient Reported Outcome Measures × 1 year × Clear all
NCT04151342 2025-12-03

CARMA-BROS

University Health Network, Toronto

Recruiting
5,500 enrolled

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡